Seminars

Oncogenic fusions are hallmarks of many aggressive pediatric cancers. However, these medically important proteins are often intrinsically disordered, presenting significant challenges as drug targets. The PAX3::FOXO1 (P3F) protein drives the high-risk fusion-positive rhabdomyosarcoma with no targeted therapy. We performed multiple Small-Molecule Microarray (SMM) screenings and developed assay pipelines to identify and validate binders to P3F. This work presents current probe discovery efforts in our lab to target P3F for precision medicine.